Compare Abbott Laboratories (ABT) vs Citigroup Inc. (C) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Citigroup Inc. — how do they compare? Abbott Laboratories trades at $95.33 (market cap $166.94B), while Citigroup Inc. trades at $137.82 (market cap $240.09B). The key difference: Citigroup Inc. is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | C | |
|---|---|---|
Market Cap | $166.94B | $240.09B |
Sector | Health | Financials |
52-Week High | $136.62 | $145.67 |
52-Week Low | $82.57 | $85.57 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Citigroup (C) trades at $140.75, up 0.59% today, with a bullish technical outlook and strong analyst support. Recent Q1 2026 earnings beat expectations, and the company expanded its services by joining LPMCL. Revenue and net income have grown steadily, with a P/E of 17.78 and a consensus price target of $151.36. The stock is near its 52-week high, reflecting positive momentum.
The outlook is positive, driven by earnings growth and strategic expansions, but risks include volatile cash flows and high debt levels. Wall Street sentiment is bullish, with 59% of analysts rating it a buy. Investors should weigh the strong fundamentals against macroeconomic and operational risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →
